Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Department of Otolaryngology, Head and Neck Surgery, Helios Hanseklinikum Stralsund, Stralsund, Germany.
Front Immunol. 2023 Mar 8;14:1075066. doi: 10.3389/fimmu.2023.1075066. eCollection 2023.
The objective of this study was to determine whether postoperative additive systemic steroid administration in chronic rhinosinusitis with nasal polyps (CRSwNP) impacted selected endoscopic, subjective and objective outcome measures.
This was a prospective, randomized, double-blind, placebo-controlled, noninferiority multicenter trial of n=106 patients with CRSwNP. All patients underwent primary functional endoscopic sinus surgery (FESS) followed by topical nasal steroids. Patients were randomized to a systemic steroid or placebo for 1 month. Patients were followed up for 2 years over 9 time points. The primary outcome measures were the differences between groups with respect to the nasal polyp score (NPS) and sinonasal quality of life (SNQoL). Secondary outcome measures included interactions with respect to the Lund-Kennedy score (LKS), sinonasal symptoms, general quality of life (GQoL), 16-item odor identification test scores, recurrence rates, need for revision surgery and mucus biomarker levels.
106 patients were randomized to either the placebo or the systemic steroid group (n=53 per group). Postoperative systemic steroids were not superior to placebo with respect to all primary (p= 0.077) and secondary outcome measures (p>0.05 for all). Reported adverse events were similar between the two groups.
In conclusion, the addition of postoperative systemic steroids after primary FESS did not confer a benefit over topical steroid nasal spray alone with respect to NPS, SNQOL, LKS, GQOL, sinonasal symptoms, smell scores, recurrence rates, the need for revision surgery or biomarkers over a short-term follow-up of up to 9 months and a long-term follow-up of up to 24 months in CRSwNP patients. Functional endoscopic surgery did, however, show a strong effect on all outcome measures, which remained relatively stable up to the endpoint at 2 years.
本研究旨在确定慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)患者术后是否需要给予全身性皮质类固醇辅助治疗,以改善某些内镜、主观和客观的预后指标。
这是一项前瞻性、随机、双盲、安慰剂对照、非劣效性多中心试验,共纳入 106 例 CRSwNP 患者。所有患者均接受了初次功能性内镜鼻窦手术(FESS),并接受了鼻局部皮质类固醇治疗。然后,患者被随机分配至全身性皮质类固醇或安慰剂组,疗程为 1 个月。患者共随访 2 年,随访时间点共 9 个。主要观察指标为各组之间鼻息肉评分(NPS)和鼻-鼻窦生活质量(SNQoL)的差异。次要观察指标包括与 Lund-Kennedy 评分(LKS)、鼻-鼻窦症状、一般生活质量(GQoL)、16 项嗅觉识别测试评分、复发率、需要再次手术以及黏液生物标志物水平相关的交互作用。
106 例患者被随机分配至安慰剂或全身性皮质类固醇组(n=53 例/组)。术后全身性皮质类固醇治疗在所有主要(p=0.077)和次要观察指标(p>0.05)方面均不比安慰剂更具优势。两组报告的不良事件相似。
总而言之,在接受初次 FESS 后加用术后全身性皮质类固醇治疗,并未使 CRSwNP 患者在 NPS、SNQOL、LKS、GQoL、鼻-鼻窦症状、嗅觉评分、复发率、需要再次手术或生物标志物方面获得比单纯鼻局部皮质类固醇治疗更优的短期(9 个月)和长期(24 个月)疗效。然而,功能性内镜手术对所有预后指标都具有很强的疗效,在 2 年的随访终点时,这些疗效仍相对稳定。